Highlights on the Risk of Pulmonary Tuberculosis in Patients on Ibrutinib Treatment: Case Report and Literature Review

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35844981

Authors

Solo Traore

Mehdi Roumila

Pirayeh Eftekhari

Hassan Farhat

Fatiha Merabet

Oumar Guira

Philippe Rousselot

Reza Azarian

Caroline Besson

Affiliations

Soon will be listed here.

References

Colado A, Genoula M, Cougoule C, Marin Franco J, Almejun M, Risnik D . Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis. Blood Cancer J. 2018; 8(11):100. PMC: 6218455. DOI: 10.1038/s41408-018-0136-x. View

Reinwald M, Silva J, Mueller N, Fortun J, Garzoni C, de Fijter J . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018; 24 Suppl 2:S53-S70. DOI: 10.1016/j.cmi.2018.02.009. View

OBrien S, Hillmen P, Coutre S, Barr P, Fraser G, Tedeschi A . Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(10):648-657.e15. DOI: 10.1016/j.clml.2018.06.016. View

Zinzani P, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F . Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leuk Res. 2019; 81:88-94. DOI: 10.1016/j.leukres.2019.04.016. View

Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P . Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016; 7(40):65968-65981. PMC: 5323207. DOI: 10.18632/oncotarget.11782. View

Wang S, Ebert T, Jaekel N, Schubert S, Niederwieser D, Al-Ali H . Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol. 2015; 94(8):1419-20. DOI: 10.1007/s00277-015-2385-0. View

Baddley J, Cantini F, Goletti D, Gomez-Reino J, Mylonakis E, San-Juan R . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018; 24 Suppl 2:S10-S20. DOI: 10.1016/j.cmi.2017.12.025. View

Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernandez-Ruiz M . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018; 24 Suppl 2:S71-S82. DOI: 10.1016/j.cmi.2018.02.003. View

OGarra A, Redford P, McNab F, Bloom C, Wilkinson R, Berry M . The immune response in tuberculosis. Annu Rev Immunol. 2013; 31:475-527. DOI: 10.1146/annurev-immunol-032712-095939. View

10.

. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000; 49(RR-6):1-51. View

11.

Dimopoulos M, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V . Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018; 378(25):2399-2410. DOI: 10.1056/NEJMoa1802917. View

12.

Morrison V . Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2007; :332-8. DOI: 10.1182/asheducation-2007.1.332. View